Scientific publications in clinical research and HTA

Research and Publications

Explore our scientific publications on statistical methods, clinical evidence and health technology assessment. Discover how our work contributes to clinical research and informs regulatory and Market Access decisions.

Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?

View publication ➝

Value in Health, September 20, 2022

Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.

Antonia Morga, DPhil, Nicholas R. Latimer, PhD; Martin Scott, MSc; Neil Hawkins, PhD; CStat, Michael Schlichting, MSc; Jixian Wang, PhD

Matching-adjusted indirect comparison via a polynomial-based non-linear optimisation method.

View publication ➝

Journal of Comparative Effectiveness Research, 4 May 2022

Jonathan Alsop, PhD; Lawrence Pont

Corona-Pandemie: Zukunfts-Überlegungen aus der Sicht epi- demiologischer Modellierung

View publication ➝

„Monitor Versorgungsforschung“ (02/22), S. 57-63

Hans-Peter Dürr, PhD; M. Eichner

Whole Blood Interferon γ Release Is a More Sensitive Marker of Prior Exposure to Coxiella burnetii Than Are Antibody Responses

View publication ➝

Frontiers in Immunology, 28 July 2021

Anja Scholzen, Margot de Vries, Hans-Peter Dürr, PhD; Hendrik-Jan Roest, Ann E. Sluder, Mark C. Poznansky, Milou L.C.E. Kouwijzer, Anja Garritsen

Estimating Comparative Effectiveness When Patients Are Switching Treatments: A Real-World Challenge

View publication ➝

Value & Outcomes Spotlight March/April 2020 p 31—33

Jonathan Alsop, PhD; Numerus Ltd, Wokingham, England, United Kingdom; Nicholas Latimer, MSc, PhD, ScHARR, University of Sheffield, Sheffield, England, United Kingdom; Melvin (Skip) Olson, PhD; Novartis Pharma AG, Basel, Switzerland; Daniel Rosenberg, PhD; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; and Martin Scott, MSc; Numerus GmbH, Tübingen, Germany

**Jonathan Alsop** & **Martin Scott**
Founders

Modern visualisation of results instead of mammoth dossiers!

View publication ➝

market access & health policy January 2020

Hans-Peter Dürr, PhD; Martin Scott, MSc

Comparing Ophthalmology Treatments Via The Integration Of IPD And Aggregate-Level Data: Which Matching Adjusted Indirect Comparison (MAIC) Approach Is Best?

View publication ➝

[Poster]. [online] Tools.ispor.org, 2018

Jonathan Alsop, PhD; Lawrence Pont

Jonathan Alsop
Operations Director

Estimands—What Do They Mean for Health Technology Assessment?

View publication ➝

Value & Outcomes Spotlight September/October 2018

Jonathan Alsop, PhD; Martin Scott, MSc

Jonathan Alsop & Martin Scott
Founders

Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases

View publication ➝

Proceedings of the National Academy of Sciences Jul 2018, 201801338

Marie Miglianico, Maarten Eldering, Hannah Slater, Neil Ferguson, Pauline Ambrose, Rosemary S. Lees, K.M.J. Koolen, Katerina Pruzinova, Magdalena Jancarova, Petr Volf, Constantianus J.M. Koenraadt, Hans-Peter Dürr, PhD; Graham Trevitt, Baiyuan Yang, Arnab K. Chatterjee, John Wisler, Angelika Sturm, Teun Bousema, Robert W. Sauerwein, Peter G. Schultz, Matthew S. Tremblay, and Koen J. Dechering

Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission

Sci Rep 7: 17680, 2017

K.J. Dechering, Hans-Peter Dürr, PhD; K.M.J. Koolen

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

Sci Rep 7: 17680, 2017

Jonathan Alsop, PhD; J. Medin, C. Cornelissen, S.V. Vormfelde, T. Ziemssen

Early CRT Monitoring using time-domain optical coherence Tomography does not add to visual acuity for predicting visual loss in patients with Central retina vein occlusion treated with intravitreal Ranibizumab

Secondary Analysis of Trial Data 2017. RETINA: March 2017 – Volume 37 – Issue 3 – p 509–514

Katy Bell, J.L. PhD; Andrew Hayen, PhD; Paul Glasziou, PhD; Andrew S. Mitchell, MMedSci; Maria Farris, BSc; Jonathan Wright, MSc; Hans-Peter Duerr, PhD; Paul Mitchell, PhD; Les Irwig, PhD

Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):793-801

S.A. Regnier, Jonathan Alsop, PhD; Jonathan Wright, MSc; R. Nixon, H. Staines, F. Fajnkuchen

Disease Characteristics and Overall Survival in Pediatric Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia after Stem Cell Transplantation

Abstract for BMT published Dec 2016

Alessandro Crotta, Christopher Keir, Julie Cleret, Simu K. Thomas, Linda Armstrong

The mixed randomized trial: combining randomized, pragmatic and observational clinical trial designs

J Comp Eff Res. 2016 Nov;5(6):569-579

Jonathan Alsop,PhD; Martin Scott, MSc; William Archey

Martin Scott, MSc; Jonathan Alsop, PhD

Hyperbolic Discounting of Effects in Economic Evaluations

View publication ➝

Value in Health, November 01, 2016. DOI

L. Fókás

Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Oedema

Adv Ther. 2016; 33: 597–609

S. Sivaprasad, Stephane A. Regnier, F. Fajnkuchen, Jonathan Wright, MSc; Alan R. Berger, Paul Mitchell, Michael Larsen

Predictors Of =20/40 Vision With Ranibizumab Treatment In Patients With Diabetic Macular Edema: A Post-Hoc Analysis Of The RESTORE Study

EURETINA European Congress, 2016. Copenhagen, Denmark

Paul Mitchell, Lawrence Pont

Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD

Ophthalmology. 2016 Jan;123(1):60-9

Sebastian M. Waldstein, MD; Jonathan Wright, MSc; James Warburton, MBBS; Philippe Margaron, PhD; Christian Simader, MD, MSc; Ursula Schmidt-Erfurth, MD

Confirmed disability improvement in patients with active multiple sclerosis treated with fingolimod versus BRACE therapies: a matched comparison of treatments from the PANGAEA and PEARL registry studies

ISPOR November 2015

Jonathan Alsop, PhD; C. Cornelissen, S.V. Vormfelde, J. Medin, T. Ziemssen

Time Off From Work: a Matched Comparison of Fingolimod and BRACE in Patients with Multiple Sclerosis from the PANGAEA and PEARL Studies (P7.019)

ePoster presentation at the American Academy of Neurology 67th Annual Meeting, 18–25 April 2015

Hans-Peter Duerr, PhD; Jonathan Alsop, PhD; N. Bergvall, C. Cornelissen, S.V. Vormfelde, T. Ziemssen

Loss of Child Well-Being: A Concept for the Metrics of Neglect and Abuse Under Separation and Divorce

Child Ind Res (2015) 8: 867

Hans-Peter Dürr, PhD; Y. Dürr-Aguilar, W. Andritzky, A. Camps, G. Deegener, C. Dum, F. Godinho, L. Li, J. Rudolph, P. Schlottke, M. Hautzinger

Effectiveness of fingolimod compared with interferons and glatiramer acetate for the treatment of multiple sclerosis: a matched comparison of treatments from the PANGAEA and PEARL studies

Neurowoche 2014, 15–19 September 2014, Munich, Germany

Hans-Peter Dürr, PhD; Jonathan Alsop, PhD; N. Bergvall, C. Cornelissen, S.V. Vormfelde, S. Moser, A. Fuchs, H.J. Schwarz, T. Ziemssen

Efficacy of Anti-VEGF and Laser Photocoagulation in the Treatment of Visual Impairment due to Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis

PLoS One. 2014 Jul 16;9(7):e102309

Stephane Regnier, William Malcolm, Felicity Allen, Jonathan Wright, MSc; Vladimir Bezlyak

Longitudinal data from the international registry for Niemann-Pick disease type C (NPC)

Molecular Genetics and Metabolism, Volume 111, issue 2 (February, 2014), p. S85. ISSN: 1096-7192 DOI: 10.1016/j.ymgme.2013.12.203 Elsevier Science

M.C. Patterson, E. Mengel, F.A. Wijburg, M.T. Vanier, B. Schwierin, A. Muller, H. Drevon, M. Pineda

Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent

PLoS Neglected Tropical Diseases. 2014;8(4):e2810.

A. Stauch, Hans-Peter Dürr, PhD; A. Picado, B. Ostyn, S. Sundar, S. Rijal, et al.

Efficacy comparison of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema- a systematic review and network meta-analysis

14th EURETINA Congress London 2014 – Poster submission

S. Regnier, Jonathan Alsop, PhD

Matucci-Cerinic M for the DUO Registry Group, 2013

Orphanet Journal of Rare Diseases 2013, 8:12

L. Guillevin, E. Hunsche, C.P. Denton, T. Krieg, B. Schwierin, D. Rosenberg, M. Silkey, Actelion Pharmaceuticals Ltd. M. Palmer, Numerus Ltd. M.C. Patterson, E. Mengel, F.A. Wijburg, A. Muller, B. Schwierin, D. Drevon, M.T. Vanier, M. Pineda

Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression

Value in Health, Volume 16, Issue 7 , Page A619, November 2013

N. Bergvall, H. Rathi, R. Nixon, H.H.Z. Thom, Jonathan Alsop, PhD; L. Dunsire

Surgical Trainee Opinions in the United Kingdom Regarding a Three Dimensional Virtual Mentoring Environment (MentorSL) in Second Life: Pilot Study Jonathan Alsop (statistical support)

JMIR Serious Games 2013| vol.1|iss.1|e2|p.6

U. Jaffer, N.W. John, N. Standfield

Effectiveness of quarterly (Q3M) versus monthly (QM) ranibizumab according to initial gains in visual acuity – an analysis of 12 month data from the EXCITE study

Invest Ophthalmol Vis Sci 2013;54: E-Abstract 3816., ARVO 2013

V. Chong, W. Amoaku, Jonathan Alsop, PhD; A. Osborne

Poster P04.128 Effects of Fingolimod on Disability Progression in Patients with Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II

Scientific Abstract Listing and Annual Meeting Information, February 12 2013

N. Bergvall, N. Sfikas, P. Chin, D. Tomic, P. von Rosenstiel, Jonathan Alsop, PhD; G. Cutter, P. Calabresi, D. Jeffery, F. Lublin, L. Kappos

Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression

Value in Health, Volume 16, issue 7 (November, 2013), p. A619. ISSN: 1098-3015 DOI: 10.1016/j.jval.2013.08.1804

N. Bergvall, H. Rathi, R. Nixon, H.H.Z. Thom, Jonathan Alsop, PhD; L. Dunsire

Digital breast tomosynthesis versus mammography and breast ultrasound: a multireader performance study

European Scociety of Radiology (2013) 23:2441–2449, DOI 10.1007/s00330-013-2863-5

F. Thibault, C. Dromain, C. Breucq, C.S. Balleyguier, C. Malhaire, L. Steyaert, A. Tardivon, E. Baldan, H. Drevon

Update From the International Registry for Niemann-Pick Disease Type C (NP-C) in Clinical Practice

Molecular Genetics and Metabolism, Volume 105, issue 2 (February, 2012), p. S51. ISSN: 1096-7192 DOI: 10.1016/j.ymgme.2011.11.129 Elsevier Science

M. Patterson, M. Pineda, E. Mengel, F. Wijburg, M. Vanier, B. Schwierin, A. Muller, Jonathan Alsop, PhD; E. Wraith

Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?

L. Watson, B.P. Wilson, Jonathan Alsop, PhD; S. Kumar

Numerous Predictions for the Future of Clinical Trial Development

CRfocus, Volume 21, Number 8 (Dec 2010 /Jan 2011) ISSN: 0968-0594

Jonathan Alsop, PhD; Martin Scott, MSc